Active, not recruitingPhase 2NCT04980222
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Glofitamab(drug)
- Enrollment
- 46 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (18)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Stanford Cancer Center, Stanford, California, United States
- University of Iowa, Iowa City, Iowa, United States
- Washington University; Wash Uni. Sch. Of Med, St Louis, Missouri, United States
- Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Baylor University Medical Center, Dallas, Texas, United States
- Aarhus Universitetshospital Skejby, Aarhus N, Denmark
- Hopital Henri Mondor, Créteil, France
- Centre Henri Becquerel, Rouen, France
- Universitair Medisch Centrum Groningen, Groningen, Netherlands
- Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdansk, Poland
- Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku, Wroclaw, Poland
- Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04980222 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05748197A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University